About Us
Ainnocence is a global biotech company that leads in generative AI for therapeutic discovery, leveraging industry-grade sequence-based proprietary technology and training data from over 16 years of expertise.
Costly high-throughput wet lab screening, expensive structure biology, and inaccurate 3D modeling processes.
A radical AI drug discovery system accelerating life-saving therapies with unprecedented speed, deep virtual throughput, and higher success rates.
Protein Design Engine
SentinusAI® is our flagship AI platform for de novo protein design and antibody engineering. Using deep learning to predict and optimize protein structures, it enables development of next-generation biologics with unprecedented speed and precision.
The platform leverages proprietary sequence-based foundation models trained on over 16 years of curated biological data, enabling rapid exploration of antibody space and optimization of therapeutic properties including binding affinity, stability, and developability.
Antibody Variants Evaluated
Small Molecule Design Engine
CarbonAI® is our advanced AI platform for small molecule drug discovery. It leverages deep learning models trained on proprietary chemical data to generate novel compounds with optimized properties for target engagement, selectivity, and drug-like characteristics.
The platform enables virtual screening of billions of compounds within hours, dramatically reducing the time and cost of hit-to-lead optimization. CarbonAI includes SynMagic™, our AI-powered retrosynthetic analysis module for practical synthesis route planning.
Synthesis Success Rate
Our AI platform suite also includes specialized engines for peptides, cell therapies, natural molecules, RNA, cosmetics, and more.
Explore All 10 PlatformsContact